60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reissued by investment analysts at Weiss Ratings in a report issued on Tuesday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on SXTP. Ascendiant Capital Markets raised their price objective on 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the company a “buy” rating in a report on Monday, June 2nd. Wall Street Zen cut 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 14th.

60 Degrees Pharmaceuticals Trading Up 3.8%

SXTP stock opened at $1.38 on Tuesday. The stock has a market cap of $2.03 million, a PE ratio of -0.03 and a beta of 2.78. The stock has a 50-day moving average price of $2.20 and a two-hundred day moving average price of $2.51. 60 Degrees Pharmaceuticals has a 1 year low of $1.26 and a 1 year high of $12.70.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.25). The firm had revenue of $0.18 million during the quarter, compared to the consensus estimate of $0.15 million. On average, analysts forecast that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.